pdufa.bio

Anaphylm

Page updated ·next FDA decision on the calendar ·Data as of Oct 19, 2026 8:08 PM ET

Anaphylm The FDA issued a Complete Response Letter on Feb 2, 2026. 1 FDA decision on record below. Every date links its source.

AQST catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Feb 2, 2026 CRLAQST

Specialist biotech funds holding AQST, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
RTW Investments7,426,471$30.9 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Anaphylm's next FDA decision or readout?

No upcoming catalyst is on our calendar for Anaphylm; 1 FDA decision is on record below.

What happened at Anaphylm's most recent FDA decision?

On Feb 2, 2026 the FDA issued a Complete Response Letter. The decision page carries the source document and the measured share-price reaction.

Has Anaphylm been approved by the FDA?

Not in our records. The FDA issued a Complete Response Letter on Feb 2, 2026.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.